amino acid sequences and solubility properties of isolated subunits, we have derived a model for the arrangement of subunits: a complex of the two core-proteins lies in the large peripheral section, cytochrome h is mainly located in the membrane, and the cytochrome c, and iron-sulphur protein extend with their catalytic domains into the small peripheral section and are anchored to the membrane each by only one protein stretch. The contact between the two monomeric units of the enzyme involves the cytochrome b and the core-proteins (Fig. I ). This structure was confirmed by small-angle neutron scattering experiments performed with the whole enzyme and subunit complexes in protonated and deuterated alkyl polyoxyethylene detergents (Perkins & Weiss, 1983) .
Structure:function relationship of uhiquinol : cytochrome reductase
We have carried out experiments in order to establish a possible functional contact between the two monomers of cytochrome reductase. We reassembled the enzyme from the dimeric hc, -subcomplex, the monomeric or dimeric corecomplex, and the monomeric iron-sulphur protein and assayed steady-state and pre-steady-state electron-transfer activities of intermediates obtained.
The experimental procedures were as follows (Linke et al., 1985) . First, equal portions of a he,-subcomplex preparation were mixed with increasing amounts of dimeric core-complex, an excess of iron-sulphur protein and phosphatidylcholine, all in Triton solution. Then the Triton was removed by adsorption to polystyrene beads. The quinol : cytochrome c reductase activity of the membranous preparations was measured and plotted versus the ratio of core-complex to bc, -complex. A hyperbolic curve was obtained. Secondly, the experiment was carried out as above but in the presence of 0.5M-NaCI. i.e. in conditions such that the core-complex is in a monomeric state (Perkins & Weiss, 1983) . If the intermediate which is monomeric with regard to the core-complex is enzymically inactive, the dependence of activity on the amount of core-complex will fdlow a sigmoidal curve. Such a curve was obtained. Thirdly, equal portions of the he, -subcomplex were incorporated into membranes as above but with increasing amounts of iron-sulphur protein and a n excess of core-complex. A sigmoidal dependence of the enzyme activity on the amount of iron-sulphur protein was obtained. This result shows that the intermediate which is monomeric with regard to the iron-sulphur protein is also enzymically inactive. For steady-state quinol : cytochrome c reductase activity, cytochrome reductase must therefore be a dimer.
We have also determined the binding of ubiquinone-I0 (Q) to the dimeric enzyme as follows (Linke et al., 1986) . Cytochrome reductase and Q were incorporated into phospholipid membranes in conditions such that the protein to phospholipid ratio was 2 (w/w) but the molar ratio of Q to enzyme dimer increased from 0 t o 4. The duroquinol: cytochrome c reductase activities of the preparations were assayed. The activity increased 10-fold with increasing content of Q following a hyperbolic curve. The initial slope value of the curve indicated that maximal activity is achieved when only one Q is bound per enzyme dimer.
We also investigated the effect of Q on the pre-steadystate reduction of cytochrome cI by duroquinol. In cytochrome reductase without Q, the reduction was slow ( I , = 0.5s) and was inhibited by myxothiazol. With increasing amount of Q, more and more cytochrome el was rapidly reduced by duroquinol (tl = 0.04s) and this fast reduction was inhibited by myxothiazol and antimycin. The relationship between the part of rapidly reduced cytochrome c, versus the molar ratio of Q to cytochrome reductase dimer indicated that the fast electron transfer from duroquinol to the two cytochrome c, subunits of dimeric cytochrome reductase involves one Q as electron-conducting group.
For further characterization of the site of action of Q, the duroquinol : cytochrome h reduction was determined in the above cytochrome reductase membranes. Surprisingly, Q inhibited this electron transfer reaction. Again, the relationship between the part of cytochrome h which was reduced with kinetics equal to the kinetics obtained with the Q-free enzyme and the molar ratio of Q to enzyme followed an almost linear curve, which had the slope value of about one Q per cytochrome reductase dimer. All these results are in accordance with a Q-cycle mechanism proposed by Mitchell (1976) on the following assumptions. Cytochrome reductase works as a dimer. Each enzyme monomer catalyses a single electron transfer from centre o to centre i and the two enzyme monomers cooperate a t centre i in the reduction of one Q to Q H 2 . Centre i contains two unequal binding sites for Q, the sites Q, and QI,. At the site Q1. Q H 2 or Q is more tightly bound. It can move ('flip-flop') to either of the two centres o but cannot exchange with the Q pool in the membrane. At the QII site, Q H 2 is more loosely bound and can exchange with the Q pool. The Q H 2 or Q a t the QI and QII sites are in rapid redox equilibrium. Duroquinol can substitute the loosely bound Q H 2 a t the QI, site but not the tightly bound Q a t the Q, site.
The structure of N A D H : ubiquinone reductcise
We have recently isolated the rotenone-sensitive N A D H : ubiquinone reductase, also from mitochondria of Neurospora c'rassu. This enzyme complex is obtained in a monomeric state, has a n M , of 620000 and contains some 25 different subunits (Ise et al., 1985) . By adding to the enzyme preparation in Triton solution mixed phospholipid-Triton micelles and then removing the Triton by dialysis. membrane crystals of the enzyme were obtained. From tilted electron microscopic views of these crystals we have calculated the low-resolution three-dimensional structure of the N A D H : ubiquinone reductase ( K . Leonard, H. Haiker & H. Weiss, unpublished work). A view parallel to the plane of the membrane of the N A D H : ubiquinone reductase and, for comparison, the ubiquinol : cytochrome c' reductase is shown in Fig. 2 The mitochondria of higher eukaryotes have a level of organization and control of biogenesis, distinct from that found in the fungi and lower eukaryotes, involving tissue specific control of mitochondrial number and protein composition in relation to cellular energy homoeostasis. Thus the mitochondrial oxidative phosphorylation system forms a variable proportion of total mitochondrial protein in cells of different tissues and likewise the number of mitochondria also varies. Not surprisingly, it is those tissues with the highest demands for ATP, such as heart, skeletal muscle and liver, which are particularly rich in mitochondria. What then tells the cell how many mitochondria it needs and what its protein composition should be? This question is particularly interesting in regard to oxidative phosphorylation because most of the protein components of the mitochondrial genome are constituents (subunits) of the inner membrane complexes of this pathway. These 13 proteins are assembled with cytoplasmically synthesized and coded subunits to make the functional complexes. Little is known at present of the mechanisms controlling mitochondrial number and composition but recent investigations of the rare human muscle diseases known as mitochondrial myopathies, a large group of which involve defects in oxidative phosphorylation, provide some insight into their operation (Morgan -Hughes e f al., 1985) . The clinical aspects of defects in the respiratory chain pertinent to my discussion are:
(a) The apparent tissue specificity of the defects in a significant proportion of patients. For example, by clinical criteria many patients only appear to express the defect in skeletal muscle. This could arise by variable penetrance of the defect or a greater ability of some tissues to avoid its metabolic consequences, for example by enhancing glycolysis. This clinical picture, at least in one case, is supported by biochemical analysis (Darley-Usmar et al., 1986) .
(b) The progressive nature of the clinical symptoms. The diseases can occur early or late in life and be of variable severity. Indeed in one case a severe deficiency of cytochrome c oxidase reverted to a benign form in an infant (DiMauro ci ul., 1985) . I shall briefly describe my experience in the analysis of one such patient who typifies the above characteristics and then will discuss various schemes to explain the aetiology of the syndrome and their implications for the broader issues of control of mitochondrial biogenesis in higher eukaryotes.
The patient I studied, in conjunction with my colleagues in the U.S.A. and Japan, was normal until age 12 when she started to develop muscle weakness and an associated lactic Abbreviation used: PCr. phosphocreatine. acidosis which has become progressively worse (DarleyUsmar et al., 1983; Kennaway et nl., 1984; Darley-Usmar & Watanabe, 1985) . Biochemical analysis revealed that the patient was functionally deficient in complex 111 and that this resulted from a deficiency of some of the polypeptide subunits of this protein. Culturing of fibroblasts and lymphocytes isolated from the patient and subsequent biochemical analysis showed that the mitochondrial genome was intact and able to synthesize a full complement of proteins and functionally that the activity absent in muscle was present in cultured cells (Darley-Usmar et al., 1986) , thus verifying the clinical picture of restricted tissue involvement of the defect (Kennaway et d . , 1984) .
More detailed analysis of total muscle proteins of the patient revealed that some components of the electrontransport chain were made in greater amounts and this, coupled with the greater number of mitochondria seen in both electron and light microscopy, may represent an attempt by the cell to overcome the defect by making more mitochondria and more 'oxidative phosphorylation units'. I interpret this effect as a response of the normal control of mitochondrial biogenesis to the abnormal cellular conditions generated by the defect, namely the decreased ATP and phosphocreatine (PCr) levels.
How can we fit these observations into a picture which can account for the aetiology of these syndromes'? Since complex I11 has components of both mitochondrial and nuclear origin, the defect could originate in either genome. But first let us consider characteristics common to a defect in either genetic system. The biochemical picture shows a deficiency of several polypeptides. This can be best explained by an initial defect, mitochondrial or nuclear, preventing assembly of the other components which then are rapidly degraded by mitochondrial proteases and are not seen on the gel. This would then appear in 'Western blotting' experiments as a generalized loss of polypeptides associated with that complex. A defect in the mitochondrial import and processing system seems unlikely since other mitochondrial complexes, for example cytochrome c oxidase, appear to function normally. Now let us consider the two possible origins of the lesion: mitochondrial or nuclear. Taking the mitochondrial option first let us ask the question what would happen if a subpopulation of mitochondria have the defect early in embryogenesis? The population might segregate as development continues so that, for example, skeletal muscle or any other tissue gained a slightly higher proportion. The metabolic consequence of this would be a decreased efficiency in generating ATP. However, this may not manifest itself until some pressure is put on the energy-generating system to produce more ATP than it is capable of supplying. In response the cell will demand more mitochondria and more 'oxidative phosphorylation units'. Indeed increased numbers of mitochondria are characteristic of these diseases. Thus the subversion of the normal mitochondria continues and symptoms become progressively worse. Those defects
